SCHEMBL558402

SCHEMBL558402

N=C(Nc1cc[c]cc1)c1cccs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.47
RAB9A P51151 9/20 0.47
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
GFER P55789 1/20 0.41
HTT P42858 1/20 0.41
HDAC1 Q13547 1/20 0.39
TP53 P04637 2/20 0.39
CASP3 P42574 1/20 0.39
CASP2 P42575 1/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
DAO P14920 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9048452 0.87 NPC1 (0.60) NPC1RAB9AKMT2AMEN1TDP1
Iodide SCHEMBL6957865 0.85 NPC1 (0.58) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL6280367 0.84 RAB9A (0.53) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL6961480 0.82 NPC1 (0.40) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL4409789 0.81 NPC1 (0.53) NPC1RAB9AKMT2AMEN1TDP1
Iodide SCHEMBL4401423 0.79 NPC1 (0.51) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL6804148 0.79 NPC1 (0.77) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL6962792 0.79 KCNK3 (0.54) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL4628336 0.78 NPC1 (0.51) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL9037874 0.78 NPC1 (0.80) NPC1RAB9AKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007509044-A 2007-04-12 JP claimed
EP-1680411-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CONTAINING CYCLOALKYL OR PYRANYL GROUPS Vertex Pharmaceuticals Incorporated (US) 2006-07-19 EP claimed
US-20050148648-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-07-07 US claimed
WO-2005035514-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CONTAINING CYCLOALKYL OR PYRANYL GROUPS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-04-21 WO claimed
US-20130012536-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-10 US disclosed
US-20120035179-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2012-02-09 US disclosed
US-20100125090-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-20 US disclosed
US-7598412-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-06 US disclosed
US-20050148648-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148648-A1 Modulators of ATP-binding cassette transporters ABCB11, ABCB1, ABCC5 NPC1 36/4885RAB9A 672/4885KMT2A 4175/4885
US-20130012536-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS ABCB11, ABCB1, ABCC5 NPC1 36/4885RAB9A 672/4885KMT2A 4175/4885
US-20100125090-A1 Modulators of ATP-Binding Cassette Transporters ABCB11, ABCB1, ABCC5 NPC1 36/4885RAB9A 672/4885KMT2A 4175/4885
US-20120035179-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS ABCB11, ABCB1, ABCC5 NPC1 36/4885RAB9A 672/4885KMT2A 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.